Zobrazeno 1 - 10
of 120
pro vyhledávání: '"DONG-JING FU"'
Autor:
Zhen-Hao Li, Ting Xu, Ya-Juan Zhang, Jing-Hang Jiang, Yu-Ze Mi, Jia-Xuan Li, Jing Shen, Yi-Rui Fu, Bo-Ying Qin, Fan Lin, Dong-Jing Fu, Mei-Jin Yue, Shu-Mei Ma, Quan-Fu Li
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectivesIn this study, we compared the dynamic changes in body composition during XELOX/SOX chemotherapy in patients with gastric cancer. Furthermore, we investigated the potential impact of these changes on the occurrence of toxic side effects.Met
Externí odkaz:
https://doaj.org/article/1a5221a297204507a40b27e3bde625ed
Autor:
Dong-Jing Fu, Qiaoyi Zhang, Ling Shi, Stephane Borentain, Shien Guo, Maju Mathews, Joana Anjo, Abigail I. Nash, Marguerite O’Hara, Carla M. Canuso
Publikováno v:
BMC Psychiatry, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior. In pooled analyses
Externí odkaz:
https://doaj.org/article/d92b57827e9447c8beae3bbfa80e1b55
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 6, Iss 1, Pp 1-11 (2022)
Abstract Background Major depressive disorder (MDD) directly impacts patients’ lives including symptoms, functioning and health-related quality-of-life (HRQoL). Patient-reported outcomes can capture these impacts, however interpretation of clinical
Externí odkaz:
https://doaj.org/article/420cb78b93404f3d8993addb4d726e58
Autor:
Xu Chen, Xuan Hou, Daisy Bai, Rosanne Lane, Chong Zhang, Carla Canuso, Gang Wang, Dong-Jing Fu
Publikováno v:
Neuropsychiatric Disease and Treatment. 19:693-707
Xu Chen,1,2,* Xuan Hou,3,* Daisy Bai,4 Rosanne Lane,5 Chong Zhang,6 Carla Canuso,7 Gang Wang,1,2 Dong-Jing Fu7 1The National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital
Autor:
Larry, Alphs, Pamela, Baker, Brianne, Brown, Dong-Jing, Fu, Ibrahim, Turkoz, Keith H, Nuechterlein
Publikováno v:
Schizophrenia Research. 248:58-63
A post hoc analysis of the Disease Recovery Evaluation and Modification (DREaM) study was conducted to evaluate time to first major treatment failure (ie, arrest/incarceration or psychiatric hospitalization) in participants with recent-onset schizoph
Autor:
Ibrahim, Turkoz, Oliver, Lopena, Giacomo, Salvadore, Gerard, Sanacora, Richard, Shelton, Dong-Jing, Fu
Publikováno v:
CNS Spectrums. :1-24
To assess the likelihood of attaining response/remission of depressive symptoms with esketamine nasal spray (ESK) plus standard of care (SoC) vs placebo nasal spray (PBO) plus SoC at 4 weeks in patients with major depressive disorder and active suici
Autor:
Naim Zaki, Li Chen, Rosanne Lane, Teodora Doherty, Wayne C. Drevets, Randall L. Morrison, Gerard Sanacora, Samuel T. Wilkinson, Vanina Popova, Dong-Jing Fu
Publikováno v:
Neuropsychopharmacology.
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, unde
Publikováno v:
Journal of Systematics and Evolution.
Publikováno v:
Palaeoworld.
Autor:
Stephane Borentain, Pooja Desai, Dong-Jing Fu, Li Nancy Chen, Rosanne Lane, Maju Mathews, Carla M Canuso
Publikováno v:
Journal of psychopharmacology (Oxford, England).
Background: Cochrane recently published a review of esketamine and other glutamate receptor modulators in depression. Aim: To address the limitations of the review, analyses of esketamine data were conducted to provide additional perspective to the r